Last reviewed · How we verify
Neurokinin-1 receptor antagonist
Neurokinin-1 receptor antagonist is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 2 development. Also known as: NK-1 receptor antagonist.
At a glance
| Generic name | Neurokinin-1 receptor antagonist |
|---|---|
| Also known as | NK-1 receptor antagonist |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) (PHASE2)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer (PHASE2)
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) (PHASE2)
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neurokinin-1 receptor antagonist CI brief — competitive landscape report
- Neurokinin-1 receptor antagonist updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Neurokinin-1 receptor antagonist
What is Neurokinin-1 receptor antagonist?
Neurokinin-1 receptor antagonist is a Small molecule drug developed by Merck Sharp & Dohme LLC.
Who makes Neurokinin-1 receptor antagonist?
Neurokinin-1 receptor antagonist is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
Is Neurokinin-1 receptor antagonist also known as anything else?
Neurokinin-1 receptor antagonist is also known as NK-1 receptor antagonist.
What development phase is Neurokinin-1 receptor antagonist in?
Neurokinin-1 receptor antagonist is in Phase 2.
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Also known as: NK-1 receptor antagonist
- Compare: Neurokinin-1 receptor antagonist vs similar drugs
- Pricing: Neurokinin-1 receptor antagonist cost, discount & access